Based on the above, we hypothesized that the concentration of KRAS mutations in plasma cfDNA is associated with outcomes in patients with advanced NSCLC treated with chemotherapy and that monitoring of ctDNA levels may provide indications of treatment efficacy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.